Key References

• Addo TA, Lincoff AM, Mehran R, et al. Impact of vascular closure devices on hemorrhagic complications after angioplasty with bivalirudin compared to heparin plus IIb/IIIa inhibitors: analysis from REPLACE-2. J Am Coll Cardiol. 2005;45(3 suppl 1):36A.
• Aguirre FV and Gill JB. Increasing benefit, reducing risk: focusing on hemorrhagic complications in percutaneous coronary intervention. J Invasive Cardiol. 2002; 14 (Suppl B):48B-54B.
• Allie DE, Lirtzman MD, Wyatt CH, et al. Bivalirudin as a foundation anticoagulant in peripheral vascular disease: a safe and feasible alternative for renal and iliac interventions. J Invasive Cardiol. 2003;15:334-342.
• Allie DE, Hall P, Shammas NW, et al. The Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE): in-hospital and 30-day results. J Invasive Cardiol. 2004;16:651-656.
• Antman EM. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation. 1994;90(4): 1624-1630.
• Antman EM, McCabe CH and Braunwald E. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: Observations from the TIMI 8 trial. Am Heart J. 2002; 143:229-234.
• Ashby CR, Daniel JL, Kunapuli SP et al. Platelet stimulatory and inhibitory receptors. In: Colman RW (ed).Hemostasis and Thrombosis. 4th edition, Philadelphia, PA. Lippincott, Williams, & Wilkins:2001:505-520.
• Attubato MJ, Feit F, Bittl JA, et al. Major hemorrhagic Is an Independent Predictor of 1 Year Mortality following Percutaneous Coronary Intervention: An Analysis from REPLACE-2. AM J Cardiol. 2004; 94: (6 Suppl 1) 39E.
• Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol. 1998;82(8B):12P-18P.
• Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invasive Cardiol. 2000;12(suppl F):27F-32F.
• Becker DL, Fredenburgh JC, Stafford AR, et al. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. J Biol Chem. 1999;274:6226-6233.
• Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 2000;35:922-928.
• Biondi-Zoccai GG, Abbate A, Liuzzo G, Biasucci LM. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol. 2003;41:1071-1077.
• Bittl JA, Chaitman B, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: the final report of the bivalirudin angioplasty study. Am Heart J. 2001;142:952-959.
• Boccara A, Benamer H, Juliard JM, et al. A randomized trial of a fixed high dose vs a weight-adjusted low dose of intravenous heparin during coronary angioplasty. Eur Heart J. 1997;18(4):631-635.
• Brener SJ, Moliterno DJ, Lincoff AM, et al. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation. 2004;110:994-998.
• Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood. 2002; 100:148-152.
• Campbell KR, Mahaffey KW, Lewis BE, et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasive Cardiol. 2000;12(suppl F):14F-19F.
• Chandler WL, Jelacic S, Boster DR, Ciol ML, Williams GD, Watkins SL et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med. 2002;346:23-32.
• Chew DP, Bhatt DL, Kimball W, et al. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol. 2003;92:919-923.
• Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation. 2001;103:961-966.
• Cohen DJ, Cosgrove RS, Berezin RH, et al. Cost effectiveness of eptifibatide in patients undergoing planned coronary stenting: results from ESPRIT trial [Abstract]. Circulation. 2001;104:1386-1387.
• Compton A. A practical cost analysis of bivalirudin. Pharmacotherapy. 2002;22(6 Pt 2):119S-127S.
• Coughlin SR. Thrombin signaling and protease-activated receptors. Nature. 2000;407:258-264.
• Dager WE, Gosselin RC, Owings JT. Argatroban therapy for antithrombin deficiency and mesenteric thrombosis: Case report and review of the literature. Pharmacotherapy. 2004;24:659-663.
• Derian CK, Damiano BP, Addo MF, et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther. 2003;304:855-861.
• Ebrahimi R, Lincoff AM. Comparison of bleeding complications using bivalirudin or heparin following percutaneous coronary interventions: a meta-analysis of different subgroups. Am J Cardiol. 2004; 94(6 Suppl 1):40E.
• Ebrahimi R, Lincoff AM , Shah, AP et al. Bivalirudin versus heparin in percutaneous coronary interventions: a meta-analysis. J Am Coll Cardiol. 2005;45 (3 Suppl 1):36A.
• Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KAA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774-782.
• EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 1998;352:87-92.
• ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000;356:2037-44. Erratum in: Lancet 2001;357:1370.
• Feit F, Bittl JA, Lincoff AM, et al. Bivalirudin reduces ischemic and hemorrhagic complications of percutaneous coronary intervention: pooled data from 10 prospective studies in 6,134 patients. J Am Coll Cardiol. 2003; 41(suppl A); 25A.
• Feit F. Optimizing percutaneous coronary intervention Significance of hemorrhagic complications. J Invasive Cardiol. 2004; 16(Suppl G): 21-25.
• Ferguson JJ, Dougherty KG, Gaos CM, et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1994;23(5):1061-1065.
• Formanek G, Frech RS, Amplatz K. Arterial thrombus formation during clinical percutaneous catheterization. Circulation. 1970;41(5):833-839.
• Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost. 1993;69(2):157-163.
• Fuchs J, Cannon CP and TIMI 7 investigators. Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 Trial. Circulation. 1995; 92:727-733.
• Gurm HS, Rajagopal V, Fathi R, et al. Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center. Am J Cardiol. 2005;95:716-721.
• The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90(4):1631-1637.
• Hartman CA, Faria CE, Mago K. Visual compatibility of bivalirudin with selected drugs. Am J Health Syst Pharm. 2004 Sep 1;61(17):1774, 1776.
• Henry TD. Overcoming heparin limitations in high-risk percutaneous coronary intervention: the alternative strategy – replacing heparin with bivalirudin. J Invasive Cardiol. 2002;14(Suppl B):19B-29B.
• Hirsh J. Heparin. N Engl J Med. 1991;324(22):1565-1574.
• Hogg PJ, Bock PE. Modulation of thrombin and heparin activities by fibrin. Thromb Haemost. 1997;77(3):424-433.
• Hogg PJ, Jackson CM, Labanowski JK, et al. Binding of fibrin monomer and heparin to thrombin in a ternary complex alters the environment of the thrombin catalytic site, reduces affinity for hirudin, and inhibits cleavage of fibrinogen. J Biol Chem. 1996;271(42):26088-26095.
• Kinnaird TD, Stabile E, Mintz GS et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary intervention. Am J Cardiol. 2003;92:930-935.
• Kleiman NS, Weitz JI. Putting heparin into perspective: its history and the evolution of its use during percutaneous coronary intervention. J Invasive Cardiol. 2000;12(suppl F):20F-26F.
• Kong DF, Topol EJ, Bittl JA, et al. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation. 1999;100:2049-2053.
• Lauer M. Cost analysis of bivalirudin in percutaneous coronary intervention. J Invasive Cardiol. 2000;12(suppl F):37F-40F.
• Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications With Hirulog for Ischemic Events Trial (CACHET). Am Heart J. 2002;143:847-853.
• Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE-1] trial). Am J Cardiol. 2004;93:1092-1096.
• Lincoff AM, Bittl JA, Harrington RA, et al for the REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853-63. Erratum in: JAMA. 2003;289:1638.
• Lincoff AM, Kleiman NS, Kereiakes DJ, et al for the REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA. 2004;292:696-703.
• Mahaffey KW, Lewis, BE, Wildermann NM, et al. The Anticoagulant Therapy with Bivalirudin to Assist in the Performance of Percutaneous Coronary Intervention in Patients with Heparin-Induced Thrombocytopenia (ATBAT) Study: Main Results. J Invasive Cardiol. 2003; 15:611-616.
• Mann, KG, Biochemistry and physiology of blood coagulation. Thromb Haemost. 1999;82(2):165-174.
• Mann KG. Thrombin formation. Chest. 2003;124:4S-10S.
• Maraganore JM, Bourdon P, Jablonski J, et al. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry. 1990;29:7095-7101.
• Marbet GA, Verstraete M, Kienast J, et al. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. J Cardiovasc Pharmacol. 1993;22:364-372.
• Marmur JD. Direct versus indirect thrombin inhibition in percutaneous coronary intervention. J Invasive Cardiol. 2002;14(suppl B):8B-18B.
• Mascelli MA, Kleiman NS, Marciniak SJ Jr, Damaraju L, Weisman HF, Jordan RE. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab. Am Heart J. 2000 Apr;139(4):696-703.
• McGarry TF Jr, Gottlieb RS, Morganroth J, et al. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J. 1992;123(6):1445-1451.
• Mehta S, Yebara S, Ibrahim M, et al. Cedars Medical Center's experience: early ambulation post PCI with use of direct thrombin inhibitor. Cath Lab Digest. 2004;12:1-4.
• Minutello RM, Wong SC, Chou ET, et al. Angiomax facilitates early sheath removal after coronary angioplasty: the AFRICA study. Am J Cardiol. 2003; 6 Suppl 1;146L.
• Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol. 2002;22:1381-1389.
• Mutch NJ, Robbie LA, Booth NA. Human thrombi contain an abundance of active thrombin. Thromb Haemost. 2001;86:1028-1034.
• Narins CR, Hillegass WB Jr, Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation. 1996;93(4):667-671.
• Ogilby JD, Kopelman HA, Klein LW, et al. Adequate heparinization during PTCA: assessment using activated clotting times. Cathet Cardiovasc Diagn. 1989;18(4):206-209.
• Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292: 1555-1562.
• Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) trial—phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1-11.
• Reed MD, Bell D. Clinical pharmacology of bivalirudin. Pharmacotherapy. 2002;22:105S-111S.
• Robson R. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol. 2000;12(suppl F):33F-36F.
• Roe MT, Peterson ED, Newby LK, et al. The influence of risk status on guideline adherence for patients with non-ST–segment elevation acute coronary syndromes. Am Heart J. 2006;151:1205-1213.
• Rosenberg RD, Bauer KA. The heparin-antithrombin system. A natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. Philadelphia, Pa: Lippincott Co. 1994:837-860.
• Sagripanti A, Cozza V, Baicchi U, Camici M, Cupisti A, Barsotti G. Increased thrombin generation in patients with chronic renal failure. Int J Clin Lab Res. 1997;27:72-75.
• Sambrano GR, Weiss EJ, Zheng Y, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature. 2001;413:74-78.
• Schussler JM, Cameron CS, Anwar A, et al. Effect of bivalirudin on length of stay in the recovery area after percutaneous coronary intervention compared with heparin alone, heparin + abciximab, or heparin + eptifibatide. Am J Cardiol. 2004;94:1417-1419.
• Shammas NW, Lemke JH, Dippel EJ, et al. Bivalirudin in peripheral vascular interventions: a single center experience. J Invasive Cardiol. 2003;15:401-404.
• Sica D. The implications of renal impairment among patients undergoing percutaneous coronary intervention. J Invasive Cardiol. 2002;14(suppl B):30B-37B.
• Siegelman SS, Caplan LH, Annes GP. Complications of catheter angiography: study with oscillometry and "pullout" angiograms. Radiology. 1968;91:251-253.
• Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). American Heart Association Web site. Available at: http://www.americanheart.org. Accessed December 6, 2006.
• Soward AL, Essed CE, Serruys PW. Coronary arterial findings after accidental death immediately after successful percutaneous transluminal coronary angioplasty. Am J Cardiol. 1985;56(12):794-795.
• Stella JF, Stella RE, Iaffaldano RA, et al. Anticoagulation with bivalirudin during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Invasive Cardiol. 2004;16:451-454.
• Stone GW. Advantages of direct thrombin inhibition in high and low risk patients. J Invasive Cardiol. 2004;16(Suppl. G):12G-17G.
• Stone GW, Bertrand M, Colombo A, et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J. 2004;148:764-775.
• Stone GW, McLaurin BT, Cox DA, et al, for the ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203-2216.
• Supplement to: Stone GW, McLaurin BT, Cox DA, et al, for the ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203-2216. Available at: http://content.nejm.org. Accessed December 6, 2006.
• Topol EJ, Bonan R, Jewitt D, et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation. 1993;87(5):1622-1629.
• Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 1999;354:2019-24. Erratum in: Lancet 2000;355:1104.
• Trissel LA , Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. IntJ Pharma Compound. 2002;6:311-315.
• Vainer J, Fleisch M, Gunnes P, et al. Low-dose heparin for routine coronary angioplasty and stenting. Am J Cardiol. 1996;78(8):964-966.
• Voeltz MD, Attubato MJ, Feit F, Lincoff AM, Manoukian SV. Anemia is associated with increased major bleeding complications and early mortality in patients undergoing percutaneous coronary intervention: implications for choices in antithrombotic therapy. J Am Coll Cardiol. 2005;45(3 Suppl):31A.
• Waller BF. Early and late morphologic changes in human coronary arteries after percutaneous transluminal coronary angioplasty. Clin Cardiol. 1983;6(8):363-372.
• Weitz JI and Bates SM. Acute coronary syndromes: A focus on thrombin. J. Invasive Cardiol. 2002; 14(suppl B) 2B-7B.
• Weitz JI, Bates SM. Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave myocardial infarction. Arch Intern Med. 2000;160(6):749-758.
• Weitz JI, Bates ER. Direct thrombin inhibitors in cardiac disease. Cardiovasc Toxicol. 2003:3;13-25.
• Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb Res. 2002;106:V275-V284.
• Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337(10):688-698.
• Xiao Z, Theroux P. Platelet activation with unfractionated heparin at the therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97:251-256.
• Yang X, Alexander KP, Chen AY, et al. The implications of blood transfusions for patients with non-ST–segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol. 2005;46:1490-1495.
• Young E, Prins M, Levine MN, et al. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost. 1992;67(6):639-643.
• Zegers E, Meursing BJ, Verheught FWA. Routine heparinisation during coronary arteriography: is it still indicated? J Am Coll Cardiol. 2000;35(suppl 2):42.

Safety Considerations

ANGIOMAX with provisional use of glycoprotein IIb/IIIa inhibitor is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), and in patients with or at risk for heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI. ANGIOMAX is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. ANGIOMAX is contraindicated in patients with active major bleeding or hypersensitivity to ANGIOMAX or its components. The most common (10%) adverse events for ANGIOMAX were back pain, pain, nausea, headache, and hypotension. An unexplained fall in blood pressure or hematocrit, or any unexplained symptom, should lead to serious consideration of a hemorrhagic event and cessation of ANGIOMAX administration. Please see complete prescribing information.